Genitourinary Cancers | Specialty

Choueiri Spotlights Activity With Novel HIF-2α Inhibitor in Heavily Pretreated RCC

May 12th 2020

Toni K. Choueiri, MD, discusses the findings from the phase 1/2 trial, the clinical implications of targeting HIF-2α in kidney cancer, and the potential utility of MK-6482 in clear cell RCC. 

Dr. Lee on Second-Line Treatment Options in RCC

May 12th 2020

Chung-Han Lee, MD, PhD, discusses second-line treatment options in renal cell carcinoma.

Dr. Powles on the 42-Month Follow-Up Data From the CheckMate-214 Trial in RCC

May 2nd 2020

Thomas Powles, MD, MBBS, MRCP, director, Barts Cancer Institute, discusses the 42-month follow-up data from the phase 3 CheckMate-214 trial in advanced renal cell carcinoma (RCC).

Dr. Petrylak on the Results of the EV-103 Trial in Bladder Cancer

May 1st 2020

Daniel P. Petrylak, MD, professor of medicine and urology, co-leader, Cancer Signaling Networks, Yale Cancer Center, and 2017 Giant of Cancer Care® in Genitourinary Cancers, discusses the results of the phase 1b/2 EV-103 trial in bladder cancer.

Long-Term Data Show Nivolumab/Ipilimumab as Preferred Frontline Regimen in RCC

April 30th 2020

Nizar M. Tannir, MD, FACP, discusses the 42-month follow-up results from the CheckMate-214 trial in advanced renal cell carcinoma and provides perspective on other approved combinations in the frontline setting.

New Therapeutic Era Sparks Fresh Questions About Nephrectomy in RCC

April 25th 2020

Although fewer patients are undergoing cytoreductive nephrectomy as systemic treatments for renal cell carcinoma improve, the modality still has a vital role to play in the treatment paradigm—even in the modern age of immune checkpoint inhibitors.

Dr. Grivas on the Future of Molecular Subtyping in Urothelial Cancer

April 23rd 2020

Petros Grivas, MD, PhD, discusses the future of molecular subtyping in urothelial cancer.

Immunotherapy Regimens May Expand Use of Neoadjuvant Therapy in MIBC

April 21st 2020

Although the standard of care for muscle-invasive bladder cancer is well established, not enough patients are being treated with curative intent.

Nivolumab Plus Cabozantinib Improves OS in CheckMate-9ER Frontline RCC Trial

April 20th 2020

Nivolumab combined with cabozantinib improved overall survival and progression-free survival compared with sunitinib in patients with previously untreated advanced renal cell carcinoma.

Sonpavde Navigates Newfound GU Cancer Treatment Considerations Amid COVID-19 Crisis

April 16th 2020

Guru P. Sonpavde, MD sheds light on how the COVID-19 pandemic has impacted treatment decisions for patients with bladder cancer, perioperative surgical concerns for patients at risk of COVID-19, and the preventative measures Dana-Farber Cancer Institute has put into place to reduce the risk of patients and providers contracting the virus.

FDA Approves Mitomycin Gel for Urothelial Cancer

April 16th 2020

The FDA has approved mitomycin gel (Jelmyto) as the first therapy to treat low-grade upper tract urothelial cancer.

Dr. Joshi on Rationale for Durvalumab/RT Combo in Localized Urothelial Carcinoma

April 15th 2020

Monika Joshi, MD, discusses the rationale for using durvalumab in combination with radiation therapy in patients with localized urothelial carcinoma.

Other Trials of Interest in Renal Cancers

April 14th 2020

Promising Second-Line Therapies for mRCC

April 14th 2020

Progress in First-Line mRCC

April 14th 2020

Combination Therapies to Overcome Resistance in mRCC

April 14th 2020

VEGF TKI Therapy After I/O in mRCC

April 14th 2020

Second-Line Therapy After I/O in mRCC

April 14th 2020

mRCC: Resistance to VEGF and I/O

April 14th 2020

IMDC Criteria and Targeted Therapy in mRCC

April 14th 2020